124 related articles for article (PubMed ID: 17595807)
1. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer.
Hotta K; Kiura K; Tabata M; Takigawa N; Fujiwara Y; Umemura S; Tanimoto M
Anticancer Res; 2007; 27(3B):1737-41. PubMed ID: 17595807
[TBL] [Abstract][Full Text] [Related]
2. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Qin HF; Qu LL; Liu H; Wang SS; Gao HJ
Asian Pac J Cancer Prev; 2013; 14(7):4205-8. PubMed ID: 23991977
[TBL] [Abstract][Full Text] [Related]
3. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
[TBL] [Abstract][Full Text] [Related]
4. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
[TBL] [Abstract][Full Text] [Related]
6. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
Clevers MR; Kastelijn EA; Peters BJM; Kelder H; Schramel FMNH
Anticancer Res; 2021 Feb; 41(2):869-876. PubMed ID: 33517292
[TBL] [Abstract][Full Text] [Related]
9. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer.
Ishiguro F; Fukui T; Mori S; Katayama T; Sakakura N; Hatooka S; Mitsudomi T
Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):242-7. PubMed ID: 21057440
[TBL] [Abstract][Full Text] [Related]
10. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Chiu CH; Shih YN; Tsai CM; Liou JL; Chen YM; Perng RP
Lung Cancer; 2007 Aug; 57(2):213-21. PubMed ID: 17449138
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
12. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
13. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Gu X; Lv T; Wu Y; Xiao Y; Yuan D; Li Y; Song Y
J Cancer Res Ther; 2014; 10(2):239-43. PubMed ID: 25022372
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
[TBL] [Abstract][Full Text] [Related]
15. [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Zhao LD; Li JL; Wang Y; Wang B; Wang HY; Hao XZ; Cui CX; Zhang XR; Shi YK
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):217-21. PubMed ID: 21575523
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G; Rauch D; Stupp R; Pless M; Stahel R; Mach N; Jost L; Widmer L; Tapia C; Bihl M; Mayer M; Ribi K; Lerch S; Bubendorf L; Betticher DC
Ann Oncol; 2008 Apr; 19(4):739-45. PubMed ID: 18096565
[TBL] [Abstract][Full Text] [Related]
17. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Keam B; Lee SJ; Kim TM; Paeng JC; Lee SH; Kim DW; Jeon YK; Chung DH; Kang KW; Chung JK; Heo DS
J Thorac Oncol; 2015 Aug; 10(8):1189-94. PubMed ID: 26200273
[TBL] [Abstract][Full Text] [Related]
18. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Hosomi Y; Tanai C; Yoh K; Goto Y; Sakai H; Kato T; Kaburagi T; Nishio M; Kim YH; Inoue A; Hasegawa Y; Isobe H; Tomizawa Y; Mori Y; Minato K; Yamada K; Ohashi Y; Kunitoh H
Expert Opin Pharmacother; 2018 Jul; 19(10):1049-1056. PubMed ID: 29871540
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
